Hydroxy desmethyl bosentan
CAS: 253688-62-9
Ref. 3D-FH23977
| 1mg | Discontinued | ||
| 2mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 500µg | Discontinued |
Product Information
- 4-(2-Hydroxy-1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide
- Benzenesulfonamide, 4-(2-hydroxy-1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)[2,2′-bipyrimidin]-4-yl]-
- Ro 64-1056
- 4-(2-Hydroxy-1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)[2,2′-bipyrimidin]-4-yl]benzenesulfonamide
Bosentan is an orally active, nonselective endothelin receptor antagonist that has been shown to be effective in the treatment of pulmonary arterial hypertension. Bosentan binds to endothelin receptors and blocks the binding of endothelin-1, which results in vasodilation. Hydroxy desmethyl bosentan is a metabolite of bosentan that has been shown to have cytotoxic activity against cancer cells. Hydroxy desmethyl bosentan has been shown to inhibit the proliferation of human liver (HepG2) cells and primary lung cancer cells (A549). The hydroxy desmethyl bosentan metabolite also has a high affinity for the endothelin A receptor. It does not affect other receptors, such as ETB receptors or ETD receptors, and does not interact with drugs metabolized by cytochrome P450 enzymes. In addition, hydroxy desmethyl bosentan is not toxic to mice or rats when administered orally at doses up
